Geoff Race's departure marks the end of an era for Minerva, as he has played a pivotal role in shaping the company's operational, financial, and clinical development strategies over the past 16 years. His leadership has been instrumental in establishing the foundation upon which Minerva operates today. Dr. Remy Luthringer, Executive Chairman and CEO, expressed gratitude for Race's contributions, highlighting his strategic guidance and commitment to improving the lives of patients.
Jim O'Connor brings over 20 years of experience in legal and business leadership across various sectors, including life sciences and technology. His previous roles include General Counsel and Chief Operating Officer at Axena Health, where he led significant legal and operational initiatives. O'Connor's appointment is expected to strengthen Minerva's mission and enhance its strategic direction as it moves forward with its clinical programs.
The company has also entered into a settlement agreement with Race, which includes a severance package and the acceleration of his stock options, allowing him to exercise them until January 1, 2030. This agreement underscores the company's commitment to ensuring a smooth transition while maintaining continuity in its leadership and strategic objectives. As Minerva navigates this leadership change, it remains focused on its goal of bringing innovative therapies to market for patients with unmet medical needs.
